Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ST-162 + unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ST-162||ST-162 is a dual kinase inhibitor of MAPK and PI3K signaling, which may result in decreased phosphorylation of Akt and Erk and subsequent tumor regression (PMID: 28775144, PMID: 29708810).|
|unspecified PD-1 antibody||Experimental PD-1 antibody||PD-L1/PD-1 antibody 69|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||ST-162 + unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, ST-162 therapy combined with an anti-PD-1 antibody resulted in greater tumor growth inhibition than treatment with either agent alone in a colorectal cancer mouse model (PMID: 28775144).||28775144|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|